Login / Signup

Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.

Ju Young ShinHye-Min ParkMin-Young LeeJa-Young JeonHyun-Jeong YooByong Duk Ye
Published in: Gut and liver (2021)
More than half of Korean UC patients had suboptimal responses to anti-TNF agents within 1 year. UC patients treated with infliximab might be less prone to suboptimal responses than those treated with adalimumab or golimumab.
Keyphrases
  • ulcerative colitis
  • rheumatoid arthritis
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes